INS and Hypoglycemia: Although insulin therapy remains the cornerstone of T1DM treatment, adjunctive therapies are gaining popularity over the last few years with the aims of improving glycaemic control and reducing insulin requirements and insulin-associated dose-dependent adverse secondary effects, such as hypoglycaemia and weight gain [61].